Skip to main content
. 2019 Jul 5;8(10):4678–4687. doi: 10.1002/cam4.2378

Figure 4.

Figure 4

Disease‐free survival in patients rendered disease‐free from (A) recurrent and (B) primary endometrial or ovarian cancer divided by dosing groups